Adoptive cell therapies (ACT) hold promise for cancer immunotherapy, but optimization is still an ongoing process. Here the authors report CD4-targeted, nanoparticle-based artificial antigen-presenting cells that expand CD4+ T cells capable of lysing tumor cell lysis in vitro, and CD8+ T cells showing antitumor activity in a mouse melanoma model.
- Ariel Isser
- Aliyah B. Silver
- Jonathan P. Schneck
